Characterization of tirzepatide-treated patients achieving HbA1c <5.7% in the SURPASS 1-4 trials

IF 10.8 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Metabolism: clinical and experimental Pub Date : 2024-06-01 DOI:10.1016/j.metabol.2024.155882

Julio Rosenstock , Stefano Del Prato , Denise Reis Franco , Luis Vázquez , Biyue Dai , Govinda Weerakkody , Laura Fernández-Landó , Angel Rodríguez , Brandon K. Bergman , Xi Chen

引用次数: 0

查看原文本刊更多论文

在 SURPASS 1-4 试验中，接受替扎帕肽治疗的患者 HbA1c <5.7% 的特征描述

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Metabolism: clinical and experimental 医学-内分泌学与代谢

CiteScore

18.90

自引率

3.10%

发文量

310

审稿时长

16 days

期刊介绍： Metabolism upholds research excellence by disseminating high-quality original research, reviews, editorials, and commentaries covering all facets of human metabolism. Consideration for publication in Metabolism extends to studies in humans, animal, and cellular models, with a particular emphasis on work demonstrating strong translational potential. The journal addresses a range of topics, including: - Energy Expenditure and Obesity - Metabolic Syndrome, Prediabetes, and Diabetes - Nutrition, Exercise, and the Environment - Genetics and Genomics, Proteomics, and Metabolomics - Carbohydrate, Lipid, and Protein Metabolism - Endocrinology and Hypertension - Mineral and Bone Metabolism - Cardiovascular Diseases and Malignancies - Inflammation in metabolism and immunometabolism